ArticleScientific reports2025
Deciphering anti-colorectal cancer potential of Avicennia alba bioactives via network pharmacology and in vitro validation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Network Pharmacology Review of Plant-Derived Anticancer Compounds in Lung, Breast, Colorectal and Prostate Cancer.International journal of molecular sciences · 2026Review
- Uncovering the potential anti-cancer compounds from Strobilanthes cusia against colorectal cancer through network pharmacology and molecular docking.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Colorectal cancer (CRC) remains a significant global health challenge, with the current therapies often being inadequate. This study investigates the potential of Avicennia alba (A. alba), a mangrove plant, as a source of new anticancer drug candidates. We employed a network pharmacology, bioinformatics approach, and in vitro experimental to explore the molecular mechanisms of action and validating activity of A. alba in CRC treatment. Cytotoxicity effect was also evaluated using MTT assay. Four constituents of A. alba-Avicenol B, Avicenol C, Avicequinone B, and Avicequinone C-were verified, leading to the identification of 10 hub genes (i.e., EGFR, PIK3CA, JAK2, MTOR, JUN, ERBB2, IGF2, SRC, MDM2, and PARP1) associated with CRC. Molecular docking and molecular dynamics simulations indicated that Avicequinone C exhibited the best docking scores and stable interactions with the top three hub genes (EGFR, PIK3CA, and JAK2). The interactions were characterized by π-sigma, alkyl, and conventional hydrogen bonds. A. alba exhibited cytotoxic activity against WiDr cell lines with an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.